Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- Regulatory Reform Panel Urges Better Trial Environment, SaMD Review
December 24, 2021
- MHLW to Set Up New Working Group to Discuss Technical Issues in Distribution: Ryukaikon
December 24, 2021
- New Generic Target Enshrined in Govt’s Updated Fiscal Reform Timeline
December 24, 2021
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
- MHLW Eyes Information Provisioning on Generic Supplies by Individual Brands
December 24, 2021
- Japan to Revise PMD Law to Create Emergency Approval System, Final Paper Due Out by Year-End
December 23, 2021
- Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
- Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
- Japan to Cut Drug Prices by 1.35% on Medical Cost Basis; No Special Rule for Adjustment Rate This Time
December 22, 2021
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
- Gist of FY2022 Drug Pricing Reform
December 22, 2021
- Look into Relationship Between COVID-19 Vaccination and Adverse Events: MHLW Panel
December 22, 2021
- Mochida’s Inhaled Treprostinil Gets Orphan Status
December 22, 2021
- Japan Expected to Cut Drug, Medical Device Prices by 160 Billion Yen on National Offers Basis
December 21, 2021
- MHLW Panel OKs “Specific-Use” Drug Designation for Dexmedetomidine
December 21, 2021
- Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
- Noxafil Contraindicated for Combined Use with Lonasen, Belsomra
December 20, 2021
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…